Other therapies for BPH patients: desmopressin, anti-cholinergic, anti-inflammatory drugs, and botulinum toxin View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2006-05-18

AUTHORS

Abdel-Rahmène Azzouzi, Marc Fourmarier, Francois Desgrandchamps, Charles Ballereau, Christian Saussine, Olivier Haillot, Bertrand Lukacs, Marian Devonec, Alexandre de la Taille

ABSTRACT

The usual treatments of benign prostate hyperplasia (BPH) including the alpha-blockers, the inhibitors of the 5-alpha reductase and the phytotherapy drugs allow significant improvements of the lower urinary tracts symptoms (LUTS). However, some patients are not responders or have side effects due to the treatments. Other therapeutic approaches described in the literature are possible in order to alleviate the LUTS. The anti-cholinergic drugs seem to be efficient against the irritating symptoms even if they are supposed to be contra-indicated when there is BPH. Anti-diuretic hormone could be useful to treat nocturia due to diuresis reversal. Inflammation is a part of the underlying mechanisms of BPH and as such the role of the anti-inflammatory drugs has to be revised. Eventually, botulinum toxin is more and more used for patients with neurological bladder and could also have a role in LUTS. If the coming clinical studies on those different treatments confirm the preliminary results, the learning societies in charge of the guidelines would have to update the decision trees by adding these new therapeutic approaches. More... »

PAGES

383-388

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00345-006-0095-x

DOI

http://dx.doi.org/10.1007/s00345-006-0095-x

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1025121452

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/16710668


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Pharmacology and Pharmaceutical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anti-Inflammatory Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antidiuretic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Botulinum Toxins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cholinergic Antagonists", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Deamino Arginine Vasopressin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prostatic Hyperplasia", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Urology, CHU, Angers, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Urology, CHU, Angers, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Azzouzi", 
        "givenName": "Abdel-Rahm\u00e8ne", 
        "id": "sg:person.0640033232.58", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0640033232.58"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Urology, CHU, Amiens, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Urology, CHU, Amiens, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fourmarier", 
        "givenName": "Marc", 
        "id": "sg:person.01140665007.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01140665007.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Urology, CHU Saint Louis, Paris, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Urology, CHU Saint Louis, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Desgrandchamps", 
        "givenName": "Francois", 
        "id": "sg:person.01324441427.88", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01324441427.88"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Urology, CHRU, Lille, France", 
          "id": "http://www.grid.ac/institutes/grid.410463.4", 
          "name": [
            "Department of Urology, CHRU, Lille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ballereau", 
        "givenName": "Charles", 
        "id": "sg:person.01317362041.62", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01317362041.62"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Urology, CHU, Strasbourg, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Urology, CHU, Strasbourg, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Saussine", 
        "givenName": "Christian", 
        "id": "sg:person.0675466517.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0675466517.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Urology, CHU, Tours, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Urology, CHU, Tours, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Haillot", 
        "givenName": "Olivier", 
        "id": "sg:person.01226220431.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01226220431.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Urology, CHU Tenon, Paris, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Urology, CHU Tenon, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lukacs", 
        "givenName": "Bertrand", 
        "id": "sg:person.01151162630.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01151162630.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Urology, CHU, Lyon, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Urology, CHU, Lyon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Devonec", 
        "givenName": "Marian", 
        "id": "sg:person.047244447.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.047244447.00"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Urology, CHU Mondor, Assistance Publique des H\u00f4pitaux de Paris, 51, avenue du Mar\u00e9chal de Lattre de Tassigny, 94000, Creteil, France", 
          "id": "http://www.grid.ac/institutes/grid.411388.7", 
          "name": [
            "Department of Urology, CHU Mondor, Assistance Publique des H\u00f4pitaux de Paris, 51, avenue du Mar\u00e9chal de Lattre de Tassigny, 94000, Creteil, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "de la Taille", 
        "givenName": "Alexandre", 
        "id": "sg:person.01264427360.56", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01264427360.56"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2006-05-18", 
    "datePublishedReg": "2006-05-18", 
    "description": "The usual treatments of benign prostate hyperplasia (BPH) including the alpha-blockers, the inhibitors of the 5-alpha reductase and the phytotherapy drugs allow significant improvements of the lower urinary tracts symptoms (LUTS). However, some patients are not responders or have side effects due to the treatments. Other therapeutic approaches described in the literature are possible in order to alleviate the LUTS. The anti-cholinergic drugs seem to be efficient against the irritating symptoms even if they are supposed to be contra-indicated when there is BPH. Anti-diuretic hormone could be useful to treat nocturia due to diuresis reversal. Inflammation is a part of the underlying mechanisms of BPH and as such the role of the anti-inflammatory drugs has to be revised. Eventually, botulinum toxin is more and more used for patients with neurological bladder and could also have a role in LUTS. If the coming clinical studies on those different treatments confirm the preliminary results, the learning societies in charge of the guidelines would have to update the decision trees by adding these new therapeutic approaches.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00345-006-0095-x", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094127", 
        "issn": [
          "0724-4983", 
          "1433-8726"
        ], 
        "name": "World Journal of Urology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "24"
      }
    ], 
    "keywords": [
      "lower urinary tract symptoms", 
      "benign prostate hyperplasia", 
      "anti-inflammatory drugs", 
      "botulinum toxin", 
      "therapeutic approaches", 
      "anti-diuretic hormone", 
      "anti-cholinergic drugs", 
      "urinary tract symptoms", 
      "new therapeutic approaches", 
      "neurological bladder", 
      "tract symptoms", 
      "BPH patients", 
      "prostate hyperplasia", 
      "clinical studies", 
      "side effects", 
      "usual treatment", 
      "patients", 
      "drugs", 
      "symptoms", 
      "treatment", 
      "significant improvement", 
      "toxin", 
      "nocturia", 
      "inflammation", 
      "desmopressin", 
      "hyperplasia", 
      "different treatments", 
      "bladder", 
      "therapy", 
      "responders", 
      "hormone", 
      "role", 
      "inhibitors", 
      "guidelines", 
      "preliminary results", 
      "contra", 
      "study", 
      "reversal", 
      "effect", 
      "improvement", 
      "mechanism", 
      "literature", 
      "reductase", 
      "results", 
      "part", 
      "approach", 
      "society", 
      "decision tree", 
      "order", 
      "charge", 
      "trees", 
      "Learning Society", 
      "phytotherapy drugs", 
      "diuresis reversal", 
      "mechanisms of BPH"
    ], 
    "name": "Other therapies for BPH patients: desmopressin, anti-cholinergic, anti-inflammatory drugs, and botulinum toxin", 
    "pagination": "383-388", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1025121452"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00345-006-0095-x"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "16710668"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00345-006-0095-x", 
      "https://app.dimensions.ai/details/publication/pub.1025121452"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:16", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_425.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00345-006-0095-x"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00345-006-0095-x'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00345-006-0095-x'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00345-006-0095-x'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00345-006-0095-x'


 

This table displays all metadata directly associated to this object as RDF triples.

227 TRIPLES      21 PREDICATES      90 URIs      81 LITERALS      15 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00345-006-0095-x schema:about N0626baa595a142978417a630ee095a37
2 N0f02a9ffb68149a58227a200a4657d45
3 N205e0d955113412fbb370d7100f3e97f
4 N3b74df0cd15846a39f53a9aad31b87fe
5 N91a2a04d3a944b3fb1cb9046e1530b31
6 Na295f138c1d1489786ce979047835b01
7 Na54004150b02453ea9cdaade1b71a63f
8 Na5ad43bb845d4161a08f324c664d60c2
9 anzsrc-for:11
10 anzsrc-for:1103
11 anzsrc-for:1115
12 schema:author Nd5e1b6f966c946e5bfd0cf16f095b01c
13 schema:datePublished 2006-05-18
14 schema:datePublishedReg 2006-05-18
15 schema:description The usual treatments of benign prostate hyperplasia (BPH) including the alpha-blockers, the inhibitors of the 5-alpha reductase and the phytotherapy drugs allow significant improvements of the lower urinary tracts symptoms (LUTS). However, some patients are not responders or have side effects due to the treatments. Other therapeutic approaches described in the literature are possible in order to alleviate the LUTS. The anti-cholinergic drugs seem to be efficient against the irritating symptoms even if they are supposed to be contra-indicated when there is BPH. Anti-diuretic hormone could be useful to treat nocturia due to diuresis reversal. Inflammation is a part of the underlying mechanisms of BPH and as such the role of the anti-inflammatory drugs has to be revised. Eventually, botulinum toxin is more and more used for patients with neurological bladder and could also have a role in LUTS. If the coming clinical studies on those different treatments confirm the preliminary results, the learning societies in charge of the guidelines would have to update the decision trees by adding these new therapeutic approaches.
16 schema:genre article
17 schema:inLanguage en
18 schema:isAccessibleForFree false
19 schema:isPartOf N26960c8984af4aedb063e0d48c6d4fa6
20 N2ac1174c443746938cc1ae6aa33e0427
21 sg:journal.1094127
22 schema:keywords BPH patients
23 Learning Society
24 anti-cholinergic drugs
25 anti-diuretic hormone
26 anti-inflammatory drugs
27 approach
28 benign prostate hyperplasia
29 bladder
30 botulinum toxin
31 charge
32 clinical studies
33 contra
34 decision tree
35 desmopressin
36 different treatments
37 diuresis reversal
38 drugs
39 effect
40 guidelines
41 hormone
42 hyperplasia
43 improvement
44 inflammation
45 inhibitors
46 literature
47 lower urinary tract symptoms
48 mechanism
49 mechanisms of BPH
50 neurological bladder
51 new therapeutic approaches
52 nocturia
53 order
54 part
55 patients
56 phytotherapy drugs
57 preliminary results
58 prostate hyperplasia
59 reductase
60 responders
61 results
62 reversal
63 role
64 side effects
65 significant improvement
66 society
67 study
68 symptoms
69 therapeutic approaches
70 therapy
71 toxin
72 tract symptoms
73 treatment
74 trees
75 urinary tract symptoms
76 usual treatment
77 schema:name Other therapies for BPH patients: desmopressin, anti-cholinergic, anti-inflammatory drugs, and botulinum toxin
78 schema:pagination 383-388
79 schema:productId N747e441e4f4445f98275089eb43c25f6
80 Na82ad6a15bbd401cb13d470c380139ad
81 Nd8cd40274cb347c2940bbfd0c1246678
82 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025121452
83 https://doi.org/10.1007/s00345-006-0095-x
84 schema:sdDatePublished 2022-01-01T18:16
85 schema:sdLicense https://scigraph.springernature.com/explorer/license/
86 schema:sdPublisher Ne155f54c73024f1c80ecc848a93f107d
87 schema:url https://doi.org/10.1007/s00345-006-0095-x
88 sgo:license sg:explorer/license/
89 sgo:sdDataset articles
90 rdf:type schema:ScholarlyArticle
91 N0626baa595a142978417a630ee095a37 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
92 schema:name Cholinergic Antagonists
93 rdf:type schema:DefinedTerm
94 N0f02a9ffb68149a58227a200a4657d45 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
95 schema:name Humans
96 rdf:type schema:DefinedTerm
97 N205e0d955113412fbb370d7100f3e97f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
98 schema:name Botulinum Toxins
99 rdf:type schema:DefinedTerm
100 N26960c8984af4aedb063e0d48c6d4fa6 schema:issueNumber 4
101 rdf:type schema:PublicationIssue
102 N2ac1174c443746938cc1ae6aa33e0427 schema:volumeNumber 24
103 rdf:type schema:PublicationVolume
104 N33f45dc4ff06482cabb142c240cf26a4 rdf:first sg:person.01140665007.42
105 rdf:rest Nc0f95b188f3f4f829051a4705a2e5693
106 N3b74df0cd15846a39f53a9aad31b87fe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Antidiuretic Agents
108 rdf:type schema:DefinedTerm
109 N41cd1c6cacd24dae93285d4783d3f73c rdf:first sg:person.01317362041.62
110 rdf:rest Nd7f53aa8ee464cae8ab8deb9921e4baf
111 N747e441e4f4445f98275089eb43c25f6 schema:name doi
112 schema:value 10.1007/s00345-006-0095-x
113 rdf:type schema:PropertyValue
114 N82c9d8c0aadd4bd2a4cf89026ea998df rdf:first sg:person.01264427360.56
115 rdf:rest rdf:nil
116 N84bb2ac4738d48bfb4558ec2d4d871f7 rdf:first sg:person.047244447.00
117 rdf:rest N82c9d8c0aadd4bd2a4cf89026ea998df
118 N90ff0a33230b4b59ac560659f8189f8b rdf:first sg:person.01226220431.42
119 rdf:rest Nc8a76b15899647bfab68161e69b7c740
120 N91a2a04d3a944b3fb1cb9046e1530b31 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Male
122 rdf:type schema:DefinedTerm
123 Na295f138c1d1489786ce979047835b01 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Anti-Inflammatory Agents
125 rdf:type schema:DefinedTerm
126 Na54004150b02453ea9cdaade1b71a63f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Prostatic Hyperplasia
128 rdf:type schema:DefinedTerm
129 Na5ad43bb845d4161a08f324c664d60c2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Deamino Arginine Vasopressin
131 rdf:type schema:DefinedTerm
132 Na82ad6a15bbd401cb13d470c380139ad schema:name dimensions_id
133 schema:value pub.1025121452
134 rdf:type schema:PropertyValue
135 Nc0f95b188f3f4f829051a4705a2e5693 rdf:first sg:person.01324441427.88
136 rdf:rest N41cd1c6cacd24dae93285d4783d3f73c
137 Nc8a76b15899647bfab68161e69b7c740 rdf:first sg:person.01151162630.55
138 rdf:rest N84bb2ac4738d48bfb4558ec2d4d871f7
139 Nd5e1b6f966c946e5bfd0cf16f095b01c rdf:first sg:person.0640033232.58
140 rdf:rest N33f45dc4ff06482cabb142c240cf26a4
141 Nd7f53aa8ee464cae8ab8deb9921e4baf rdf:first sg:person.0675466517.55
142 rdf:rest N90ff0a33230b4b59ac560659f8189f8b
143 Nd8cd40274cb347c2940bbfd0c1246678 schema:name pubmed_id
144 schema:value 16710668
145 rdf:type schema:PropertyValue
146 Ne155f54c73024f1c80ecc848a93f107d schema:name Springer Nature - SN SciGraph project
147 rdf:type schema:Organization
148 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
149 schema:name Medical and Health Sciences
150 rdf:type schema:DefinedTerm
151 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
152 schema:name Clinical Sciences
153 rdf:type schema:DefinedTerm
154 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
155 schema:name Pharmacology and Pharmaceutical Sciences
156 rdf:type schema:DefinedTerm
157 sg:journal.1094127 schema:issn 0724-4983
158 1433-8726
159 schema:name World Journal of Urology
160 schema:publisher Springer Nature
161 rdf:type schema:Periodical
162 sg:person.01140665007.42 schema:affiliation grid-institutes:None
163 schema:familyName Fourmarier
164 schema:givenName Marc
165 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01140665007.42
166 rdf:type schema:Person
167 sg:person.01151162630.55 schema:affiliation grid-institutes:None
168 schema:familyName Lukacs
169 schema:givenName Bertrand
170 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01151162630.55
171 rdf:type schema:Person
172 sg:person.01226220431.42 schema:affiliation grid-institutes:None
173 schema:familyName Haillot
174 schema:givenName Olivier
175 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01226220431.42
176 rdf:type schema:Person
177 sg:person.01264427360.56 schema:affiliation grid-institutes:grid.411388.7
178 schema:familyName de la Taille
179 schema:givenName Alexandre
180 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01264427360.56
181 rdf:type schema:Person
182 sg:person.01317362041.62 schema:affiliation grid-institutes:grid.410463.4
183 schema:familyName Ballereau
184 schema:givenName Charles
185 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01317362041.62
186 rdf:type schema:Person
187 sg:person.01324441427.88 schema:affiliation grid-institutes:None
188 schema:familyName Desgrandchamps
189 schema:givenName Francois
190 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01324441427.88
191 rdf:type schema:Person
192 sg:person.047244447.00 schema:affiliation grid-institutes:None
193 schema:familyName Devonec
194 schema:givenName Marian
195 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.047244447.00
196 rdf:type schema:Person
197 sg:person.0640033232.58 schema:affiliation grid-institutes:None
198 schema:familyName Azzouzi
199 schema:givenName Abdel-Rahmène
200 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0640033232.58
201 rdf:type schema:Person
202 sg:person.0675466517.55 schema:affiliation grid-institutes:None
203 schema:familyName Saussine
204 schema:givenName Christian
205 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0675466517.55
206 rdf:type schema:Person
207 grid-institutes:None schema:alternateName Department of Urology, CHU Saint Louis, Paris, France
208 Department of Urology, CHU Tenon, Paris, France
209 Department of Urology, CHU, Amiens, France
210 Department of Urology, CHU, Angers, France
211 Department of Urology, CHU, Lyon, France
212 Department of Urology, CHU, Strasbourg, France
213 Department of Urology, CHU, Tours, France
214 schema:name Department of Urology, CHU Saint Louis, Paris, France
215 Department of Urology, CHU Tenon, Paris, France
216 Department of Urology, CHU, Amiens, France
217 Department of Urology, CHU, Angers, France
218 Department of Urology, CHU, Lyon, France
219 Department of Urology, CHU, Strasbourg, France
220 Department of Urology, CHU, Tours, France
221 rdf:type schema:Organization
222 grid-institutes:grid.410463.4 schema:alternateName Department of Urology, CHRU, Lille, France
223 schema:name Department of Urology, CHRU, Lille, France
224 rdf:type schema:Organization
225 grid-institutes:grid.411388.7 schema:alternateName Department of Urology, CHU Mondor, Assistance Publique des Hôpitaux de Paris, 51, avenue du Maréchal de Lattre de Tassigny, 94000, Creteil, France
226 schema:name Department of Urology, CHU Mondor, Assistance Publique des Hôpitaux de Paris, 51, avenue du Maréchal de Lattre de Tassigny, 94000, Creteil, France
227 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...